Niagen Bioscience Inc Statistics
Share Statistics
Niagen Bioscience Inc has 77.75M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 77.75M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 17 |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 2.13M, so 2.73% of the outstanding
shares have been sold short.
| Short Interest | 2.13M |
| Short % of Shares Out | 2.73% |
| Short % of Float | 4.18% |
| Short Ratio (days to cover) | 3.01 |
Valuation Ratios
The PE ratio is 53.05 and the forward
PE ratio is 42.23.
Niagen Bioscience Inc's PEG ratio is
-0.22.
| PE Ratio | 53.05 |
| Forward PE | 42.23 |
| PS Ratio | 4.55 |
| Forward PS | 4.4 |
| PB Ratio | 9.84 |
| P/FCF Ratio | 37.97 |
| PEG Ratio | -0.22 |
Financial Ratio HistoryEnterprise Valuation
Niagen Bioscience Inc has an Enterprise Value (EV) of 411.74M.
| EV / Sales | 4.13 |
| EV / EBITDA | 44.71 |
| EV / EBIT | 34 |
| EV / FCF | 34.47 |
Financial Position
The company has a current ratio of 3.57,
with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.57 |
| Quick Ratio | 3.06 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.29 |
| Debt / FCF | 0.22 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 18.55% and Return on Invested Capital is 14.53%.
| Return on Equity | 18.55% |
| Return on Assets | 12.52% |
| Return on Invested Capital | 14.53% |
| Revenue Per Employee | $957,663.46 |
| Profits Per Employee | $82,211.54 |
| Employee Count | 104 |
| Asset Turnover | 1.46 |
| Inventory Turnover | 4.14 |
Taxes
| Income Tax | 305K |
| Effective Tax Rate | 3.44% |
Stock Price Statistics
The stock price has increased by 162.78% in the
last 52 weeks. The beta is 1.95, so Niagen Bioscience Inc's
price volatility has been higher than the market average.
| Beta | 1.95 |
| 52-Week Price Change | 162.78% |
| 50-Day Moving Average | 7.16 |
| 200-Day Moving Average | 5.39 |
| Relative Strength Index (RSI) | 72.26 |
| Average Volume (20 Days) | 994,124 |
Income Statement
In the last 12 months, Niagen Bioscience Inc had revenue of 99.6M
and earned 8.55M
in profits. Earnings per share was 0.1.
| Revenue | 99.6M |
| Gross Profit | 61.59M |
| Operating Income | 7.73M |
| Net Income | 8.55M |
| EBITDA | 9.21M |
| EBIT | 7.73M |
| Earnings Per Share (EPS) | 0.1 |
Full Income StatementBalance Sheet
The company has 44.51M in cash and 2.65M in
debt, giving a net cash position of 41.86M.
| Cash & Cash Equivalents | 44.51M |
| Total Debt | 2.65M |
| Net Cash | 41.86M |
| Retained Earnings | -181.91M |
| Total Assets | 68.28M |
| Working Capital | 46.15M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 12.11M
and capital expenditures -163K, giving a free cash flow of 11.95M.
| Operating Cash Flow | 12.11M |
| Capital Expenditures | -163K |
| Free Cash Flow | 11.95M |
| FCF Per Share | 0.14 |
Full Cash Flow StatementMargins
Gross margin is 61.84%, with operating and profit margins of 7.76% and 8.58%.
| Gross Margin | 61.84% |
| Operating Margin | 7.76% |
| Pretax Margin | 8.89% |
| Profit Margin | 8.58% |
| EBITDA Margin | 9.25% |
| EBIT Margin | 7.76% |
| FCF Margin | 11.99% |
